187 related articles for article (PubMed ID: 30776650)
1. Acute treatment with the PDE4 inhibitor roflumilast improves verbal word memory in healthy old individuals: a double-blind placebo-controlled study.
Blokland A; Van Duinen MA; Sambeth A; Heckman PRA; Tsai M; Lahu G; Uz T; Prickaerts J
Neurobiol Aging; 2019 May; 77():37-43. PubMed ID: 30776650
[TBL] [Abstract][Full Text] [Related]
2. Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults.
Van Duinen MA; Sambeth A; Heckman PRA; Smit S; Tsai M; Lahu G; Uz T; Blokland A; Prickaerts J
Neuropharmacology; 2018 Mar; 131():31-38. PubMed ID: 29241652
[TBL] [Abstract][Full Text] [Related]
3. The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses.
Vanmierlo T; Creemers P; Akkerman S; van Duinen M; Sambeth A; De Vry J; Uz T; Blokland A; Prickaerts J
Behav Brain Res; 2016 Apr; 303():26-33. PubMed ID: 26794595
[TBL] [Abstract][Full Text] [Related]
4. Acute administration of roflumilast enhances sensory gating in healthy young humans in a randomized trial.
Heckman PRA; Van Duinen MA; Blokland A; Uz T; Prickaerts J; Sambeth A
Psychopharmacology (Berl); 2018 Jan; 235(1):301-308. PubMed ID: 29098341
[TBL] [Abstract][Full Text] [Related]
5. An experimental medicine study of the phosphodiesterase-4 inhibitor, roflumilast, on working memory-related brain activity and episodic memory in schizophrenia patients.
Gilleen J; Farah Y; Davison C; Kerins S; Valdearenas L; Uz T; Lahu G; Tsai M; Ogrinc F; Reichenberg A; Williams SC; Mehta MA; Shergill SS
Psychopharmacology (Berl); 2021 May; 238(5):1279-1289. PubMed ID: 30536081
[TBL] [Abstract][Full Text] [Related]
6. The Phosphodiesterase-4 Inhibitor Roflumilast, a Potential Treatment for the Comorbidity of Memory Loss and Depression in Alzheimer's Disease: A Preclinical Study in APP/PS1 Transgenic Mice.
Wang H; Zhang FF; Xu Y; Fu HR; Wang XD; Wang L; Chen W; Xu XY; Gao YF; Zhang JG; Zhang HT
Int J Neuropsychopharmacol; 2020 Dec; 23(10):700-711. PubMed ID: 32645141
[TBL] [Abstract][Full Text] [Related]
7. The effects of roflumilast, a phosphodiesterase type-4 inhibitor, on EEG biomarkers in schizophrenia: A randomised controlled trial.
Gilleen J; Nottage J; Yakub F; Kerins S; Valdearenas L; Uz T; Lahu G; Tsai M; Ogrinc F; Williams SC; Ffytche D; Mehta MA; Shergill SS
J Psychopharmacol; 2021 Jan; 35(1):15-22. PubMed ID: 32854568
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia.
Livingston NR; Hawkins PC; Gilleen J; Ye R; Valdearenas L; Shergill SS; Mehta MA
J Psychopharmacol; 2021 Sep; 35(9):1099-1110. PubMed ID: 33908296
[TBL] [Abstract][Full Text] [Related]
9. Safety and Pharmacodynamics of the PDE4 Inhibitor Roflumilast in Advanced B-cell Malignancies.
Kelly K; Mejia A; Suhasini AN; Lin AP; Kuhn J; Karnad AB; Weitman S; Aguiar RC
Clin Cancer Res; 2017 Mar; 23(5):1186-1192. PubMed ID: 27542768
[No Abstract] [Full Text] [Related]
10. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.
Singh D; Lea S; Mathioudakis AG
Drugs; 2021 Nov; 81(16):1821-1830. PubMed ID: 34731461
[TBL] [Abstract][Full Text] [Related]
11. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine.
Böhmer GM; Gleiter CH; Mörike K; Nassr N; Walz A; Lahu G
J Clin Pharmacol; 2011 Apr; 51(4):594-602. PubMed ID: 20484614
[TBL] [Abstract][Full Text] [Related]
12. Mucociliary Clearance in Former Tobacco Smokers with Both Chronic Obstructive Pulmonary Disease and Chronic Bronchitis and the Effect of Roflumilast.
Laube BL; Carson KA; Sharpless G; Paulin LM; Hansel NN
J Aerosol Med Pulm Drug Deliv; 2019 Aug; 32(4):189-199. PubMed ID: 30964381
[No Abstract] [Full Text] [Related]
13. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects.
Feng H; Wang C; He W; Wu X; Li S; Zeng Z; Wei M; He B
Metab Brain Dis; 2019 Apr; 34(2):583-591. PubMed ID: 30610438
[TBL] [Abstract][Full Text] [Related]
16. Roflumilast attenuates cognitive deficits in estrogen insufficient rats.
Goyal A; Garabadu D
Behav Pharmacol; 2020 Oct; 31(7):671-687. PubMed ID: 32516271
[TBL] [Abstract][Full Text] [Related]
17. Trial of Roflumilast Cream for Chronic Plaque Psoriasis.
Lebwohl MG; Papp KA; Stein Gold L; Gooderham MJ; Kircik LH; Draelos ZD; Kempers SE; Zirwas M; Smith K; Osborne DW; Trotman ML; Navale L; Merritt C; Berk DR; Welgus H;
N Engl J Med; 2020 Jul; 383(3):229-239. PubMed ID: 32668113
[TBL] [Abstract][Full Text] [Related]
18. Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD.
Park TS; Kang J; Lee JS; Oh YM; Lee SD; Lee SW
Int J Chron Obstruct Pulmon Dis; 2019; 14():871-879. PubMed ID: 31354255
[TBL] [Abstract][Full Text] [Related]
19. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
20. Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.
Rogliani P; Calzetta L; Cazzola M; Matera MG
Expert Opin Drug Saf; 2016 Aug; 15(8):1133-46. PubMed ID: 27279341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
